Fennec Pharmaceuticals (TSE:FRX) Sets New 52-Week Low at $9.00

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$9.00 and last traded at C$10.27, with a volume of 8748 shares changing hands. The stock had previously closed at C$13.72.

Fennec Pharmaceuticals Trading Down 27.0 %

The stock's fifty day moving average is C$13.60 and its 200 day moving average is C$13.06. The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 3.56. The stock has a market cap of C$271.54 million, a P/E ratio of -16.73 and a beta of 0.40.

Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last released its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The company had revenue of C$13.25 million for the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. As a group, equities research analysts predict that Fennec Pharmaceuticals Inc. will post 0.4239973 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Senior Officer Adrian J. Haigh purchased 22,222 shares of the business's stock in a transaction dated Monday, April 15th. The shares were purchased at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. In other news, Senior Officer Adrian J. Haigh purchased 22,222 shares of the stock in a transaction dated Monday, April 15th. The shares were acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. Also, Senior Officer Robert Christopher Andrade sold 13,975 shares of the stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of C$10.90, for a total transaction of C$152,345.67. In the last three months, insiders sold 39,112 shares of company stock valued at $390,926. Insiders own 14.60% of the company's stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.